Evidence map›Paper›PMID 38344467›Full record

ReviewFrontiers in neuroscience2024

Fluid biomarkers in cerebral amyloid angiopathy.

Seyed Mehrdad Savar, Bin Ma, Eugene Hone, Farzana Jahan, Shaun Markovic, Steve Pedrini, Soudabeh Shemehsavar, Vandhana Easwaran, Kevin Taddei, Samantha Gardener and 11 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 3 countries.

Seyed Mehrdad SavarCentre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.
Bin MaCentre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.
Eugene HoneSchool of Medical and Health Sciences, Sarich Neuroscience Research Institute, Edith Cowan University, Nedlands, WA, Australia.
Farzana JahanCentre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.
Shaun MarkovicCentre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.
Steve PedriniSchool of Medical and Health Sciences, Sarich Neuroscience Research Institute, Edith Cowan University, Nedlands, WA, Australia.
Soudabeh ShemehsavarCentre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.
Vandhana EaswaranCentre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.
Kevin TaddeiSchool of Medical and Health Sciences, Sarich Neuroscience Research Institute, Edith Cowan University, Nedlands, WA, Australia.
Samantha GardenerSchool of Medical and Health Sciences, Sarich Neuroscience Research Institute, Edith Cowan University, Nedlands, WA, Australia.
Jasmeer P ChhatwalMassachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Ellis S van EttenDepartment of Neurology, Leiden University Medical Center, Leiden, Netherlands.
Matthias J P van OschDepartment of Radiology, Leiden University Medical Center, Leiden, Netherlands.
Daniel ClarkeAustralian Alzheimer's Research Foundation, Nedlands, WA, Australia.
Anastazija GnjecAustralian Alzheimer's Research Foundation, Nedlands, WA, Australia.
Mark A van BuchemDepartment of Radiology, Leiden University Medical Center, Leiden, Netherlands.
Marieke J H WermerDepartment of Neurology, Leiden University Medical Center, Leiden, Netherlands.
Graeme J HankeyMedical School, The University of Western Australia, Crawley, WA, Australia.
Steven M GreenbergHaemorrhagic Stroke Research Program, Massachusetts General Hospital Stroke Research Center, Boston, MA, United States.
Ralph N MartinsCentre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.
Hamid R SohrabiCentre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.
Murdoch University · AUEdith Cowan University · AULeiden University Medical Center · NLAustralian Alzheimer’s Research Foundation · AUMassachusetts General Hospital · USSir Charles Gairdner Hospital · AUUniversity of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerebral amyloid angiopathy (CAA) is a type of cerebrovascular disorder characterised by the accumulation of amyloid within the leptomeninges and small/medium-sized cerebral blood vessels. Typically, cerebral haemorrhages are one of the first clinical manifestations of CAA, posing a considerable challenge to the timely diagnosis of CAA as the bleedings only occur during the later disease stages. Fluid biomarkers may change prior to imaging biomarkers, and therefore, they could be the future of CAA diagnosis. Additionally, they can be used as primary outcome markers in prospective clinical trials. Among fluid biomarkers, blood-based biomarkers offer a distinct advantage over cerebrospinal fluid biomarkers as they do not require a procedure as invasive as a lumbar puncture. This article aimed to provide an overview of the present clinical data concerning fluid biomarkers associated with CAA and point out the direction of future studies. Among all the biomarkers discussed, amyloid β, neurofilament light chain, matrix metalloproteinases, complement 3, uric acid, and lactadherin demonstrated the most promising evidence. However, the field of fluid biomarkers for CAA is an under-researched area, and in most cases, there are only one or two studies on each of the biomarkers mentioned in this review. Additionally, a small sample size is a common limitation of the discussed studies. Hence, it is hard to reach a solid conclusion on the clinical significance of each biomarker at different stages of the disease or in various subpopulations of CAA. In order to overcome this issue, larger longitudinal and multicentered studies are needed.

Indexed as

amyloid betacerebral amyloid angiopathydifferential diagnosisfamilial cerebral amyloid angiopathyfluid biomarkerssurrogate endpoints

Identifiers

PMID38344467
PMCPMC10853435
OpenAlexW4391261462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.